Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text

Medicine, Oncology, Pharmacology +12

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

Medicine, Oncology, Pharmacotherapy +11

Sensitivity Analysis in Observational Research: Introducing the E-Value

Tyler J. VanderWeele, Peng Ding · Annals of Internal Medicine · 2017 · 5.7K citations · Full text

Public Health, Biostatistics, Causal Inference +14

Sorafenib in Advanced Hepatocellular Carcinoma

재연 정 · 2008 · 5.6K citations

Medicine, Oncology, Pharmacology +12